Lumigan
Lumigan Manufacturer – About AbbVie
Sep 5, 2025
Globally, billions of people live with vision impairment, and the World Health Organization estimates that at least 1 billion cases are preventable or untreated. Leading causes include refractive errors, cataracts, and glaucoma—conditions that burden aging populations socially and economically. Limited access to timely care highlights the need for pharmaceutical innovation, driving the development of therapies that can slow disease progression and help preserve long-term vision.
One such therapy is Lumigan (bimatoprost), a prostaglandin analog used to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. Approved by the U.S. FDA in 2001, Lumigan has become a widely prescribed treatment and a key part of global glaucoma management. Originally developed by Allergan, it now belongs to AbbVie’s eye care portfolio, following AbbVie’s 2020 acquisition of Allergan.
In this article, we’ll take a closer look at AbbVie’s role as Lumigan’s current manufacturer, explore its strategic priorities in eye care, including research investment and patient access programs, and consider what this transition means for Lumigan’s future development and global availability.
Key Takeaways
- AbbVie, formed in 2013 after its spin-off from Abbott, is a global biopharmaceutical leader with a strategically important presence in ophthalmology.
- Lumigan (bimatoprost), FDA-approved in 2001, is prescribed to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.
- AbbVie became the Lumigan manufacturer following its 2020 acquisition of Allergan, expanding its eye care portfolio.
- The Allergan merger strengthened AbbVie’s reach, integrating Lumigan into a diversified lineup that also includes Restasis, Alphagan P, and Refresh.
- AbbVie upholds strict global quality standards, ensuring Lumigan remains safe, effective, and consistent across markets.
- AbbVie’s innovation in ophthalmology focuses on sustained-release delivery systems (e.g., Durysta implant) and research in retinal disease.
- While immunology and oncology remain AbbVie’s largest franchises, ophthalmology represents a strategic growth area addressing significant unmet global needs.
Book a Meeting
About: Trusted by over 2,000+ global clients since 2014, Maylips has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Maylips offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world. If you’re looking to buy Lumigan online, contact our sales team for guidance.
Corporate Background of AbbVie and Role in Ophthalmology
AbbVie was founded in 2013 as a spin-off from Abbott Laboratories, emerging as a global biopharmaceutical company with strong research-driven programs across immunology, oncology, neuroscience, and ophthalmology. While ophthalmology is not its largest revenue area, it remains a strategically important field because of the rising global need for glaucoma and ocular treatments.
As the Lumigan manufacturer, AbbVie plays a central role in ensuring this product remains available worldwide for patients with glaucoma and ocular hypertension. Lumigan, with its active ingredient bimatoprost, is one of AbbVie’s best-known ophthalmic products.
The company’s investment in this space supports patients’ access to FDA-approved therapies, while also collaborating with regulatory bodies in Europe, Asia, and other regions to ensure compliance and maintain availability. Their reputation reflects a balance of safety, quality, and broad market reach in ophthalmology.
AbbVie’s Acquisition of Allergan and Impact on Lumigan’s Development
AbbVie’s $63 billion acquisition of Allergan in 2020 expanded its footprint beyond immunology blockbusters like Humira and into neuroscience, aesthetics, and eye care. This deal brought Lumigan, a prostaglandin analog for lowering intraocular pressure, into AbbVie’s growing eye health portfolio.
Key Impacts on Lumigan’s Development
- Portfolio Integration: Lumigan joined a strong eye care lineup that already included products for glaucoma, dry eye, and ocular surface disease.
- R&D Support: AbbVie’s resources and infrastructure opened opportunities for formulation refinement and delivery innovation, even though Lumigan itself is a legacy product.
- Commercial Reach: AbbVie’s global network improved access to Lumigan in regions where glaucoma prevalence is rising and treatment gaps remain.
- Pipeline Priorities: While Lumigan is established, AbbVie is also focusing on newer treatments, which could eventually shape how Lumigan is positioned in the market.
Although Lumigan was not the centerpiece of the Allergan acquisition, its inclusion in AbbVie’s portfolio placed it within a stronger, innovation-driven framework. This could support lifecycle strategies, such as sustained-release delivery systems or pairing with other agents, to improve patient adherence.
AbbVie’s Product Portfolio in Eye Care
AbbVie’s eye care division reflects a broad, research-based approach that grew significantly after the Allergan merger. Its current portfolio addresses both front- and back-of-the-eye conditions, combining legacy therapies with next-generation research.
Key Therapeutic Areas
- Glaucoma: Products like Lumigan and Alphagan P help manage intraocular pressure.
- Dry Eye Disease: Restasis and Refresh provide support for tear production and ocular surface comfort.
- Retinal Disease: AbbVie is advancing treatments for age-related macular degeneration and diabetic retinopathy, including gene therapy collaborations with REGENXBIO.
- Ocular Inflammation and Allergies: Medications such as Acular and Acuvail offer anti-inflammatory relief.
Innovation Highlights
- Exploring sustained-release delivery systems to reduce dosing frequency.
- Advancing gene therapy research for chronic retinal conditions.
- Leveraging advanced imaging to monitor disease progression and treatment response.
By combining expertise from multiple areas, AbbVie takes a cross-disciplinary approach, linking ophthalmology with neuroscience and immunology to investigate shared disease pathways. This approach strengthens its ability to deliver both established treatments and future therapies.
Quality Standards, Innovation, and Future Pipeline for Lumigan and Related Products
AbbVie adheres to strict global pharmaceutical standards, ensuring that Lumigan and related products remain consistent, safe, and effective. Every batch undergoes rigorous testing before reaching patients. Even routine questions from patients, like “Does Lumigan need to be refrigerated?”, highlight how critical clear, standardized guidance is to preserve both safety and confidence in treatment. In the U.S., Lumigan is stored at 2–25°C and does not require refrigeration, though labeling may vary internationally.
Looking forward, AbbVie is investing in technologies that extend the usefulness of its ophthalmic portfolio. While no new bimatoprost molecules are under development, the company continues to support lifecycle management strategies—for example, the Durysta implant, a sustained-release form of bimatoprost approved in the U.S. for glaucoma patients. Beyond Lumigan, AbbVie’s pipeline is more heavily focused on retinal diseases, where it is exploring gene therapy, biologics, and novel delivery platforms.
By maintaining high manufacturing standards and investing in innovation, AbbVie is reinforcing its role in ophthalmology while continuing to deliver trusted products like Lumigan.
Conclusion
AbbVie has become a key player in ophthalmology, strengthened by its 2020 acquisition of Allergan and the integration of products like Lumigan. As the Lumigan manufacturer, AbbVie combines a diverse eye care portfolio with rigorous global quality standards.
From bimatoprost-based treatments like Lumigan to next-generation research in retinal disease and delivery systems, AbbVie is shaping the future of ophthalmic care. While immunology and oncology remain AbbVie’s largest franchises, its commitment to vision health reflects a broader mission: advancing innovation in areas of growing global need.
FAQs
1. Who is the manufacturer of Lumigan?
AbbVie, a global biopharmaceutical company with a strong presence in ophthalmology, manufactures Lumigan.
2. What is Lumigan used for?
It is prescribed to reduce intraocular pressure in patients with glaucoma or ocular hypertension.
3. How does Lumigan work?
Its active ingredient, bimatoprost, increases the outflow of fluid from the eye through the uveoscleral and trabecular pathways. This effectively lowers pressure and reduces glaucoma-related risks.
4. Is Lumigan an FDA-approved product?
Yes. Lumigan was FDA-approved in 2001 and is also authorized by other regulatory agencies worldwide. However, labeling and instructions may vary by region.
5. What role did Allergan play in Lumigan’s development?
Allergan originally developed Lumigan before AbbVie acquired the company in 2020, after which AbbVie assumed responsibility for its production and distribution.
6. Are there alternatives to Lumigan?
Yes. Alternatives include other prostaglandin analogs (latanoprost, travoprost) and different IOP-lowering classes like beta-blockers, alpha agonists, and carbonic anhydrase inhibitors.
7. Does AbbVie have other eye care products?
Yes. AbbVie markets a range of products for glaucoma, dry eye disease, ocular inflammation, and retinal conditions, combining legacy therapies with ongoing research into innovative treatments.
Talk with our sales representative.
Book a Meeting
References
ABBVIE completes transformative acquisition of Allergan. AbbVie News Center. Published May 8, 2020. https://news.abbvie.com/2020-05-08-AbbVie-Completes-Transformative-Acquisition-of-Allergan
World Health Organization: WHO. Blindness and vision impairment. Published August 10, 2023. https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment
Malik K, Dua A. Prostaglandins. StatPearls – NCBI Bookshelf. Published November 21, 2022. https://www.ncbi.nlm.nih.gov/books/NBK553155/
Nawrat A. AbbVie acquires Allergan: unpicking the year-long approval process. Pharmaceutical Technology. https://www.pharmaceutical-technology.com/features/abbvie-allergan-acquisition-63bn/. Published May 12, 2020.
